IL6 and metabolic disease: The systemic increased levels of adiponectin and inflammatory cytokines, such as tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), has also been associated with hypertrophy of adipose tissue and with augmented risk of metabolic disorders such as cardiovascular diseases, fatty liver disease and T2D [74].